In this report, we show that erlotinib enhances STAT3 phosphorylation by downregulation of its phosphatase PTPMeg2 leading to elevated levels of Bcl2/Bcl-XL, which reduces sensitivity of SCCHN to erlotinib treatment. This evidence concerns the gene STAT3 and head and neck squamous cell carcinoma.